| 9.49 -0.16 (-1.66%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.97 | 1-year : | 13.99 |
| Resists | First : | 10.25 | Second : | 11.97 |
| Pivot price | 8.3  |
|||
| Supports | First : | 7.5 |
Second : | 5.8 |
| MAs | MA(5) : | 9.09 |
MA(20) : | 8.21 |
| MA(100) : | 8.14 |
MA(250) : | 8.24 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 82.3 |
D(3) : | 78.4 |
| RSI | RSI(14): 65.3 |
|||
| 52-week | High : | 11.84 | Low : | 4.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ETNB ] has closed below upper band by 10.0%. Bollinger Bands are 9.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.63 - 9.68 | 9.68 - 9.72 |
| Low: | 9.23 - 9.28 | 9.28 - 9.32 |
| Close: | 9.41 - 9.49 | 9.49 - 9.56 |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Thu, 22 May 2025
Is 89bio (NASDAQ:ETNB) A Risky Investment? - simplywall.st
Tue, 13 May 2025
Why 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance
Fri, 09 May 2025
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Tue, 06 May 2025
89bio Schedules Double Fireside Chats: Key Updates Coming at Major Healthcare Conferences - Stock Titan
Thu, 01 May 2025
89bio (ETNB) Poised for Success with Advancements in MASH Trials - GuruFocus
Fri, 18 Apr 2025
89bio: A Buy With Strong Market Opportunity In MASH And SHTG - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 146 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 104 (%) |
| Shares Short | 17,310 (K) |
| Shares Short P.Month | 15,230 (K) |
| EPS | -3.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40 % |
| Return on Equity (ttm) | -69.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -400 (M) |
| Levered Free Cash Flow | -262 (M) |
| PE Ratio | -2.75 |
| PEG Ratio | 0 |
| Price to Book value | 2.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|